A study established an EVDX signature (defined as a weighted sum of the expression of the following 8 EV markers) by linear discriminant analysis of eight breast cancer-associated serum EVPs (CA15-3, CA125, CEA, HER2, EGFR, PSMA, EpCAM, and VEGF), which can distinguish metastatic breast cancer (MBC) patients from non-MBC patients and healthy donors with an overall accuracy of 91.1% [84]. The gene discussed is ERBB2; the disease is breast cancer.